273 related articles for article (PubMed ID: 27464795)
21. Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node‑negative early breast cancer: 15-year follow-up.
Donizy P; Pietrzyk G; Halon A; Kozyra C; Gansukh T; Lage H; Surowiak P; Matkowski R
Oncol Rep; 2014 Apr; 31(4):1777-87. PubMed ID: 24535158
[TBL] [Abstract][Full Text] [Related]
22. TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome.
Aleskandarany MA; Negm OH; Rakha EA; Ahmed MA; Nolan CC; Ball GR; Caldas C; Green AR; Tighe PJ; Ellis IO
Breast Cancer Res Treat; 2012 Nov; 136(2):419-27. PubMed ID: 23053644
[TBL] [Abstract][Full Text] [Related]
23. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
24. FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer.
Habashy HO; Rakha EA; Aleskandarany M; Ahmed MA; Green AR; Ellis IO; Powe DG
Breast Cancer Res Treat; 2011 Aug; 129(1):11-21. PubMed ID: 21336599
[TBL] [Abstract][Full Text] [Related]
25. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM
Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086
[TBL] [Abstract][Full Text] [Related]
26. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
[TBL] [Abstract][Full Text] [Related]
27. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
[TBL] [Abstract][Full Text] [Related]
28. DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers.
Vaclová T; Gómez-López G; Setién F; Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Benítez J; Osorio A
Breast Cancer Res Treat; 2015 Jul; 152(2):271-82. PubMed ID: 26071757
[TBL] [Abstract][Full Text] [Related]
29. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas.
Yoshikawa K; Ogawa T; Baer R; Hemmi H; Honda K; Yamauchi A; Inamoto T; Ko K; Yazumi S; Motoda H; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
Int J Cancer; 2000 Oct; 88(1):28-36. PubMed ID: 10962436
[TBL] [Abstract][Full Text] [Related]
30. Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.
Aleskandarany MA; Negm OH; Green AR; Ahmed MA; Nolan CC; Tighe PJ; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):339-48. PubMed ID: 24771047
[TBL] [Abstract][Full Text] [Related]
31. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.
Rakha EA; Pinder SE; Paish EC; Robertson JF; Ellis IO
J Pathol; 2004 Jul; 203(3):754-61. PubMed ID: 15221934
[TBL] [Abstract][Full Text] [Related]
32. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Paish EC; Macmillan RD; Ellis IO; Green AR
Breast Cancer Res Treat; 2010 Jul; 122(1):45-53. PubMed ID: 19701705
[TBL] [Abstract][Full Text] [Related]
34. High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients.
Sokolenko AP; Bulanova DR; Iyevleva AG; Aleksakhina SN; Preobrazhenskaya EV; Ivantsov AO; Kuligina ESh; Mitiushkina NV; Suspitsin EN; Yanus GA; Zaitseva OA; Yatsuk OS; Togo AV; Kota P; Dixon JM; Larionov AA; Kuznetsov SG; Imyanitov EN
Int J Cancer; 2014 May; 134(10):2352-8. PubMed ID: 24470238
[TBL] [Abstract][Full Text] [Related]
35. RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.
Martin RW; Orelli BJ; Yamazoe M; Minn AJ; Takeda S; Bishop DK
Cancer Res; 2007 Oct; 67(20):9658-65. PubMed ID: 17942895
[TBL] [Abstract][Full Text] [Related]
36. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
[TBL] [Abstract][Full Text] [Related]
37. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51.
Plo I; Laulier C; Gauthier L; Lebrun F; Calvo F; Lopez BS
Cancer Res; 2008 Nov; 68(22):9404-12. PubMed ID: 19010915
[TBL] [Abstract][Full Text] [Related]
38. Effect of germ-line genetic variation on breast cancer survival in a population-based study.
Goode EL; Dunning AM; Kuschel B; Healey CS; Day NE; Ponder BA; Easton DF; Pharoah PP
Cancer Res; 2002 Jun; 62(11):3052-7. PubMed ID: 12036913
[TBL] [Abstract][Full Text] [Related]
39. Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Lee HB; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
Breast Cancer Res Treat; 2019 May; 175(1):117-127. PubMed ID: 30671767
[TBL] [Abstract][Full Text] [Related]
40. Loss of Dicer expression is associated with breast cancer progression and recurrence.
Khoshnaw SM; Rakha EA; Abdel-Fatah TM; Nolan CC; Hodi Z; Macmillan DR; Ellis IO; Green AR
Breast Cancer Res Treat; 2012 Sep; 135(2):403-13. PubMed ID: 22821364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
